Isabelle Vande Broek

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3

Ann De Becker, Paul Van Hummelen, Marleen Bâkkus et al. · Haematologica · 2007 · 229 citations · Full text

Life Sciences, Cell Biology, Hematology +17

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

Jinsong Hu, Damian Handisides, Els Van Valckenborgh et al. · Blood · 2010 · 156 citations

Medicine, Oncology, Pharmacology +14

Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3

Isabelle Vande Broek, Kewal Asosingh, Karin Vanderkerken et al. · British Journal of Cancer · 2003 · 126 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma

Sarah Deleu, Miguel Lemaire, Janine Arts et al. · Cancer Research · 2009 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17